Last reviewed · How we verify
NCT03775005
Short Course Radiation Therapy in Palliative Treatment of Abdominal Cancer
NA trial testing standard treatment in Abdomen Tumors in 82 participants. Status unknown.
8 November 2022
Quick facts
| Lead sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 8 November 2017 |
| Primary completion | 8 November 2022 |
| Estimated completion | 8 November 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- standard treatment
- short course treatment
Conditions studied
- Abdomen Tumors — all drugs for Abdomen Tumors →
- Radiotherapy — all drugs for Radiotherapy →
- Palliative Care — all drugs for Palliative Care →
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →
Who can join
18 and older, any sex, with Abdomen Tumors or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic abdominal malignant lesions
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03775005
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of standard treatment
Trials testing the same drug.
- NCT07236645 — Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy · Phase 2 · not yet recruiting
- NCT07172100 — To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-a · Phase 2 · enrolling by invitation
- NCT07045883 — Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss · NA · active not recruiting
- NCT06961201 — Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-s · Phase 3 · not yet recruiting
- NCT06872034 — The Efficacy and Safety of Venostan in Promoting Postoperative Swelling Reduction in Patients With Ankle Fractures · NA · recruiting
Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials
Trials by the same sponsor.
- NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
- NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
- NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
- NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
- NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03775005 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Last refreshed: 13 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03775005.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing